Starting a TRT Program at Your Practice: The Complete Guide

Testosterone replacement therapy (TRT) represents one of the strongest recurring revenue opportunities in cash-pay medicine. Unlike episodic treatments, TRT patients require ongoing therapy for years or decades, creating predictable monthly revenue with low clinical overhead once patients are stabilized.

This guide covers every step of launching a TRT program at your practice: patient identification and screening, laboratory requirements, prescribing protocols, monitoring schedules, pharmacy selection, compliance considerations, and the business economics that make TRT one of the most attractive program additions for medical practices.

The Market Opportunity for TRT

The demand for testosterone therapy continues to grow, driven by increasing awareness of hypogonadism symptoms and the availability of cash-pay treatment options.

Key market facts:

• An estimated 4 to 5 million American men have symptomatic testosterone deficiency, according to the American Urological Association
• Only about 5% to 10% of hypogonadal men currently receive treatment
• The market for testosterone therapy is projected to exceed $1.8 billion annually
• Patient awareness is growing through direct-to-consumer advertising and online health communities

For medical practices, this creates a large addressable market of symptomatic patients actively seeking treatment, many of whom prefer the convenience and privacy of cash-pay programs over navigating insurance coverage for hormone therapy.

Step 1: Determine Your Practice Model

Before launching, define how TRT fits within your existing practice:

Standalone TRT Program

Some practices build dedicated men’s health or hormone optimization programs where TRT is the primary service. This model works well for:

• New practices building from scratch
• Telehealth-focused practices
• Practices targeting male patients specifically

TRT as an Add-On Program

Most practices add TRT to complement existing services. This model works well for:

• Family medicine and internal medicine practices
• Integrative and functional medicine practices
• Anti-aging and longevity practices
• Practices already running peptide or GLP-1 programs

The add-on model is typically lower risk because you already have patient flow, infrastructure, and clinical staff in place.

Step 2: Patient Screening and Identification

Who Is a Candidate for TRT?

According to the Endocrine Society Clinical Practice Guidelines, TRT is indicated for men with:

• Documented low testosterone: Total testosterone below 300 ng/dL on at least two morning measurements
• Symptomatic presentation: Fatigue, decreased libido, erectile dysfunction, decreased muscle mass, increased body fat, depressed mood, cognitive difficulties, or decreased bone mineral density
• No contraindications: Active prostate cancer, untreated severe obstructive sleep apnea, uncontrolled heart failure, hematocrit above 54%, or desire for fertility in the near term

Screening Workflow

1. Symptom assessment: Use validated questionnaires (ADAM questionnaire or qADAM) to document symptoms
2. Medical history review: Identify contraindications, prior hormone use, relevant medications
3. Physical examination: Assess body composition, testicular exam, assess for gynecomastia (in-person or via telehealth where appropriate)
4. Laboratory testing: Order baseline labs (detailed below)

Identifying Candidates in Your Existing Patient Base

If you already see male patients for other conditions, you likely have candidates in your current practice:

• Men on antidepressants or with treatment-resistant depression
• Men with metabolic syndrome or type 2 diabetes
• Men reporting fatigue, low energy, or decreased motivation
• Men over 40 presenting with non-specific complaints
• Men taking opioids chronically (opioid-induced hypogonadism)

A simple screening protocol for male patients over 35 can identify candidates who may benefit from testosterone evaluation.

Step 3: Laboratory Requirements

Baseline Labs (Before Initiating TRT)

Lab Timing and Logistics

• Morning draw is essential. Testosterone levels peak in early morning and decline throughout the day. Draws after 10 AM may show falsely low values.
• Fasting preferred for accurate lipid and metabolic panels.
• Two low readings required for diagnosis per Endocrine Society guidelines (though many cash-pay practices proceed with a single confirmed low reading plus clear symptoms).

Lab Options for Cash-Pay Practices

• Direct lab partnerships: Negotiate cash-pay rates with Quest, Labcorp, or regional labs ($100 to $200 per comprehensive panel)
• In-house phlebotomy: Higher margin but requires CLIA waiver and staffing
• Patient-directed labs: Patients order through discount lab services; you review results

Step 4: Prescribing Protocols

Testosterone Formulations

For cash-pay practices using compounding pharmacies, the most common formulations are:

Testosterone Cypionate (Injectable)

• Most common formulation for TRT
• Typical starting dose: 100 to 200 mg per week (split into 2 injections for stable levels)
• Administered subcutaneously or intramuscularly
• Compounded cost: $30 to $60 per month

Testosterone Enanthate (Injectable)

• Similar pharmacokinetics to cypionate
• Interchangeable in most protocols
• Some patients report preference for one ester over the other

Testosterone Cream (Topical)

• Applied daily to scrotal or inner thigh skin
• Typical concentration: 10% to 20% compounded cream
• Good option for patients who prefer not to inject
• Compounded cost: $40 to $80 per month

Starting Protocols

A typical starting protocol for a new TRT patient:

1. Testosterone cypionate: 100 mg twice weekly (subcutaneous) or 150 mg weekly (if patient prefers fewer injections)
2. Anastrozole (if needed): 0.25 to 0.5 mg twice weekly for estrogen management (prescribed based on baseline estradiol and monitored at follow-up)
3. HCG (optional): 500 to 1000 IU twice weekly for testicular maintenance and fertility preservation

Dose Optimization

The goal is symptom resolution with testosterone levels in the upper-normal range (typically 600 to 1000 ng/dL):

• Check levels at 6 to 8 weeks after starting
• Draw trough levels (immediately before next injection)
• Adjust dose in 20 to 25 mg increments
• Recheck 6 to 8 weeks after any dose change
• Most patients stabilize within 2 to 3 dose adjustments

Step 5: Monitoring Schedule

Follow-Up Timeline

Red Flags to Monitor

• Hematocrit above 54%: Requires dose reduction or therapeutic phlebotomy. Polycythemia is the most common TRT side effect per the FDA prescribing information for testosterone.
• PSA rising rapidly: More than 1.4 ng/mL increase within 12 months warrants urology referral
• Significant estradiol elevation: Above 50 to 60 pg/mL with symptoms (water retention, gynecomastia) may require anastrozole adjustment
• Sleep apnea worsening: TRT can exacerbate untreated sleep apnea
• Mood changes: Rare but monitor for irritability or mood instability

Step 6: Pharmacy Selection

For TRT programs, your compounding pharmacy partner handles testosterone preparation and patient fulfillment.

Key Pharmacy Criteria for TRT

• DEA-registered for Schedule III controlled substances
• State-licensed in your state and patient states (for telehealth practices)
• Sterility testing for injectable formulations
• Certificates of analysis available for all compounds
• Direct-to-patient shipping with appropriate temperature controls
• Electronic prescribing integration for controlled substances (EPCS-capable)

Pharmacy Options

Karpa Health integrates with established compounding pharmacies that specialize in hormone therapy, including Empower Pharmacy and other vetted partners. This eliminates the need to independently evaluate and contract with pharmacies.

Step 7: Compliance Considerations

DEA Requirements

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. Prescribers must:

• Maintain active DEA registration
• Use EPCS (Electronic Prescribing for Controlled Substances) where required by state law
• Keep appropriate records of all controlled substance prescriptions
• Follow state-specific controlled substance prescribing regulations

Telehealth Prescribing for Controlled Substances

The Ryan Haight Act generally requires an in-person examination before prescribing controlled substances. However, exceptions exist:

• The COVID-era telehealth flexibilities (DEA has proposed permanent rules for telehealth prescribing)
• State-specific telehealth prescribing allowances
• Practitioners operating within a DEA-registered hospital or clinic

Check current DEA guidance and your state medical board rules for the most up-to-date telehealth prescribing requirements for Schedule III substances.

Documentation Requirements

Maintain thorough documentation for each TRT patient:

• Documented low testosterone (lab values)
• Symptom documentation (questionnaire scores)
• Discussion of risks and benefits
• Informed consent
• Ongoing monitoring documentation
• Rationale for dose adjustments

The Business Case for TRT

Revenue Model

• Monthly program fee: $150 to $300 per patient
• Pharmacy wholesale cost: $30 to $80 per patient monthly
• Net margin: $100 to $200 per patient monthly

Patient Lifetime Value

TRT patients represent the highest lifetime value cohort in cash-pay medicine:

• Average retention: 3 to 5+ years (many stay for 10+ years)
• Monthly churn rate: 3% to 5% (well below other program types)
• Lifetime value at $200/month for 4 years: $9,600 per patient

Scaling Economics

At 100 patients, a TRT program generates over $160,000 in annual net profit with approximately 8 to 10 hours of clinical time per week.

Cross-Sell Opportunities

TRT patients are excellent candidates for complementary programs:

• Peptide therapy: BPC-157 for recovery, CJC-1295/Ipamorelin for growth hormone optimization
• GLP-1 weight loss: Many TRT patients have concurrent weight management goals
• Performance optimization: Patients interested in TRT are often interested in broader hormone optimization

A practice offering TRT alongside peptide therapy and GLP-1 weight loss can serve multiple needs per patient, increasing revenue per patient significantly.

Launching with Karpa Health

Karpa Health simplifies TRT program launch by providing:

• Digital patient intake with TRT-specific questionnaires and symptom scoring
• AI-powered clinical review that flags lab abnormalities and contraindications
• One-click prescribing with integrated EPCS for controlled substances
• Pharmacy routing to vetted, DEA-registered compounding partners
• Automated monitoring reminders for follow-up labs and check-ins
• Patient communication for lab results, appointment scheduling, and refill coordination

Most practices go from decision to first TRT patient within two weeks using the Karpa platform. For more on the financial opportunity, see our cash-pay revenue model guide.

Implementation Checklist

Use this checklist to track your TRT program launch:

1. Define your TRT program model (standalone vs. add-on)
2. Establish lab partnerships or in-house capabilities
3. Create prescribing protocols and dosing guidelines
4. Set up monitoring schedule and follow-up workflows
5. Select and credential with compounding pharmacy
6. Verify DEA registration and controlled substance compliance
7. Build patient intake forms and consent documents
8. Set pricing and program structure
9. Create marketing materials targeting appropriate patient demographics
10. Launch patient acquisition campaigns

For practices ready to move quickly, Karpa Health handles items 4 through 8 through the platform, reducing launch time from weeks to days. If you plan to offer telehealth-based TRT services, review our telehealth prescribing compliance guide for state-by-state requirements. Visit our TRT solution page to learn more, or check our FAQ for additional questions about getting started.